I-Mab Regains Nasdaq Compliance with Minimum Bid Price

I-MAB ( (IMAB) ) has shared an update.

On June 11, 2025, I-Mab announced that it had regained compliance with Nasdaq’s $1.00 minimum bid price requirement, ensuring its American Depositary Shares will continue to be listed and traded on Nasdaq. This compliance was achieved by maintaining a minimum closing bid price for 10 consecutive business days, concluding on June 10, 2025, thereby closing the matter with Nasdaq.

The most recent analyst rating on (IMAB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.

Spark’s Take on IMAB Stock

According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.

The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.

To see Spark’s full report on IMAB stock, click here.

More about I-MAB

I-Mab is a U.S.-based, global biotech company focused on developing precision immuno-oncology agents for cancer treatment. The company’s pipeline is led by givastomig, a bispecific antibody designed to treat Claudin 18.2-positive gastric cancers, with potential applications in other solid tumors.

Average Trading Volume: 427,615

Technical Sentiment Signal: Buy

Current Market Cap: $208.4M

See more insights into IMAB stock on TipRanks’ Stock Analysis page.